November 03, 2023
1 min watch
Save
VIDEO: APX3330 shows promise in slowing diabetic retinopathy progression
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
SAN FRANCISCO — In this Healio Video Perspective from Eyecelerator@AAO, George Magrath, MD, MBA, MS, CEO of Ocuphire Pharma, provides an update on APX3330 for the treatment of diabetic retinopathy.
APX3330 is “well tolerated, and really shows promise to potentially slow or prevent the progression of non-proliferative diabetic retinopathy to vision-threatening disease,” he said.
Magrath also discussed the results of the end-of-phase 2 meeting with the FDA for APX3330.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Magrath reports being the CEO of Ocuphire Pharma.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.